Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Appl Mater Interfaces ; 16(4): 4348-4360, 2024 Jan 31.
Article in English | MEDLINE | ID: mdl-38253997

ABSTRACT

Prostate cancer is the most common malignancy diagnosed in men. Androgens are directly related to its pathogenesis. Inhibition of the androgen receptor (AR) is considered to be the most promising therapeutic approach for the treatment of prostate cancer. In this study, a new type of pH-responsive dual androgen-blocking nanodrug (FASC MIPs) based on a molecularly imprinted polymer has been designed and synthesized. The nanodrug could selectively sequester testosterone from the prostate tumor through specific molecular imprinting sites and simultaneously deliver the AR inhibitory drug bicalutamide, which ultimately leads to enhanced synergistic therapy of prostate cancer. FASC MIPs demonstrate excellent pH responsiveness in a simulated tumor microenvironment due to the presence of chitosan and significantly inhibit the growth of prostate cancer cells (LNCaP cells) by blocking the G1 phase of cytokinesis. Additionally, the nanodrug also displayed excellent antitumor properties in a xenograft mouse model of prostate cancer without any sign of detrimental effects on healthy tissues and organs. Both in vitro and in vivo studies verified the augmented and synergistic therapeutic effects of FASC MIPs, and the proposed dual-androgen-blocking strategy could explore novel avenues in prostate cancer treatment.


Subject(s)
Androgens , Prostatic Neoplasms , Male , Humans , Animals , Mice , Androgens/therapeutic use , Molecularly Imprinted Polymers/therapeutic use , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/pathology , Magnetic Phenomena , Hydrogen-Ion Concentration , Cell Line, Tumor , Tumor Microenvironment
2.
J Drug Target ; 31(8): 878-888, 2023 09.
Article in English | MEDLINE | ID: mdl-37566392

ABSTRACT

A magnetic molecularly imprinted polymer (MMIP) was synthesised and tested for an in vivo rheumatoid arthritis (RA) rat model. Magnetite coated with mesoporous silica (Fe2O3@mSi) was used as core for surface imprinting, dopamine was used as monomer and methotrexate (MTX) was loaded directly during polymerisation. The amount of MTX loaded on MMIPs reached 201.165 ± 0.315 µmol/g. Characterisation of the polymers was done via SEM, TEM, and FTIR. The pharmacological effect of the selected MMIP was evaluated in a Complete Freund's Adjuvant (CFA) induced arthritis rat model where a 3D magnet bearing construct was designed for targeted delivery of MMIPs. The parameters evaluated were the change in paw edoema, paw diameter, gait score, and animal's weight. Results revealed a tendency of MMIP to significantly improve the measured parameters which was confirmed with histopathological findings. In conclusion, the improvement in the arthritic signs associated with MMIP treatment compared to free MTX, indicated successful targeting of MMIPs to the site of inflammation.


Subject(s)
Arthritis, Rheumatoid , Molecularly Imprinted Polymers , Rats , Animals , Molecularly Imprinted Polymers/therapeutic use , Arthritis, Rheumatoid/drug therapy , Methotrexate/pharmacology , Methotrexate/therapeutic use , Inflammation , Magnetic Phenomena
3.
J Nanobiotechnology ; 19(1): 305, 2021 Oct 06.
Article in English | MEDLINE | ID: mdl-34615526

ABSTRACT

Molecular imprinting (MI) is a technique that creates a template of a molecule for improving complementary binding sites in terms of size and shape to a peptide, protein, bacteria, mammalian cell, or virus on soft materials (such as polymers, hydrogels, or self-assembled materials). MI has been widely investigated for over 90 years in various industries but is now focused on improved tissue engineering, regenerative medicine, drug delivery, sensors, diagnostics, therapeutics and other medical applications. Molecular targets that have been studied so far in MI include those for the major antigenic determinants of microorganisms (like bacteria or viruses) leading to innovations in disease diagnosis via solid-phase extraction separation and biomimetic sensors. As such, although not widely investigated yet, MI demonstrates much promise for improving the detection of and treatment for the current Coronavirus Disease of 2019 (COVID-2019) pandemic as well as future pandemics. In this manner, this review will introduce the numerous applications of MI polymers, particularly using proteins and peptides, and how these MI polymers can be used as improved diagnostic and therapeutic tools for COVID-19.


Subject(s)
COVID-19/diagnosis , Molecularly Imprinted Polymers/therapeutic use , SARS-CoV-2/isolation & purification , Antibodies , Drug Carriers , Humans , Molecular Imprinting , Molecularly Imprinted Polymers/chemistry , Peptides , Proteins , Receptors, Cell Surface
4.
ACS Appl Mater Interfaces ; 13(34): 40332-40341, 2021 Sep 01.
Article in English | MEDLINE | ID: mdl-34412467

ABSTRACT

As we all know, inhibiting the activity of dihydrofolate reductase (DHFR) has always been an effective strategy for folate antimetabolites to treat tumors. In the past, it mainly relied on chemical drugs. Here, we propose a new strategy, (3-propanecarboxyl)triphenylphosphonium bromide (CTPB)-modified molecularly imprinted polymer nanomedicine (MIP-CTPB). MIP-CTPB prepared by imprinting the active center of DHFR can specifically bind to the active center to block the catalytic activity of DHFR, thereby inhibiting the synthesis of DNA and ultimately inhibiting the tumor growth. The modification of CTPB allows the nanomedicine to be targeted and enriched in mitochondria, where DHFR is abundant. The confocal laser imaging results show that MIP-CTPB can target mitochondria. Cytotoxicity experiments show that MIP-CTPB inhibits HeLa cell proliferation by 42.2%. In vivo experiments show that the tumor volume of the MIP-CTPB-treated group is only one-sixth of that of the untreated group. The fluorescent and paramagnetic properties of the nanomedicine enable targeted fluorescence imaging of mitochondria and T2-weighted magnetic resonance imaging of tumors. This research not only opens up a new direction for the application of molecular imprinting, but also provides a new idea for tumor antimetabolic therapy guided by targeted mitochondrial imaging.


Subject(s)
Antineoplastic Agents/therapeutic use , Folic Acid Antagonists/therapeutic use , Molecularly Imprinted Polymers/therapeutic use , Nanoparticles/therapeutic use , Neoplasms/drug therapy , Tetrahydrofolate Dehydrogenase/metabolism , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacology , Catalytic Domain/drug effects , Cell Proliferation/drug effects , Folic Acid Antagonists/chemical synthesis , Folic Acid Antagonists/pharmacology , HeLa Cells , Humans , Mice, Nude , Mitochondria/drug effects , Mitochondria/enzymology , Molecularly Imprinted Polymers/chemical synthesis , Molecularly Imprinted Polymers/pharmacology , Nanoparticles/chemistry , Organophosphorus Compounds/chemical synthesis , Organophosphorus Compounds/pharmacology , Organophosphorus Compounds/therapeutic use , Tetrahydrofolate Dehydrogenase/chemistry
5.
Small ; 16(27): e1906644, 2020 07.
Article in English | MEDLINE | ID: mdl-32101378

ABSTRACT

Billions of dollars are invested into the monoclonal antibody market every year to meet the increasing demand in clinical diagnosis and therapy. However, natural antibodies still suffer from poor stability and high cost, as well as ethical issues in animal experiments. Thus, developing antibody substitutes or mimics is a long-term goal for scientists. The molecular imprinting technique presents one of the most promising strategies for antibody mimicking. The molecularly imprinted polymers (MIPs) are also called "molecularly imprinted synthetic antibodies" (MISAs). The breakthroughs of key technologies and innovations in chemistry and material science in the last decades have led to the rapid development of MISAs, and their molecular affinity has become comparable to that of natural antibodies. Currently, MISAs are undergoing a revolutionary transformation of their applications, from initial adsorption and separation to the rising fields of biomedicine. Herein, the fundamental chemical design of MISAs is examined, and then current progress in biomedical applications is the focus. Meanwhile, the potential of MISAs as qualified substitutes or even to transcend the performance of natural antibodies is discussed from the perspective of frontier needs in biomedicines, to facilitate the rapid development of synthetic artificial antibodies.


Subject(s)
Antibodies , Biomedical Technology , Molecularly Imprinted Polymers , Animals , Antibodies/chemistry , Biomedical Technology/trends , Molecularly Imprinted Polymers/chemistry , Molecularly Imprinted Polymers/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...